Hepatocellular carcinoma (HCC) ranks number three among the most frequent causes of death from solid tumors worldwide. With obesity and fatty liver diseases as risk factors on the rise, HCC represents an ever increasing challenge. While there is still no curative treatment for most patients numerous novel drugs have been proposed, but most ultimately failed in phase III trials. This manuscript targets therapeutic advances and most burning issues. Expert key point summaries and urgent research agenda are provided regarding risk factors, including microbiota, need for prognostic and predictive biomarkers and the equivocal role of liver biopsy. Therapeutic topics highlighted are locoregional techniques, combination therapies and the potential of immunotherapy. Finally the manuscript provides a critical evaluation of novel targets and strategies for personalized treatment of HCC.

中文翻译：

---

肠道圆桌会议论文：肝细胞癌最新进展精选

肝细胞癌（HCC）在全球实体瘤最常见的死亡原因中排名第三。随着肥胖和脂肪肝等危险因素的增加，肝癌面临着日益严峻的挑战。虽然大多数患者仍然没有治愈方法，但人们提出了许多新药，但大多数最终在 III 期试验中失败。这份手稿针对的是治疗进展和最紧迫的问题。提供了关于风险因素的专家要点总结和紧急研究议程，包括微生物群、对预后和预测生物标志物的需求以及肝活检的模棱两可的作用。强调的治疗主题是局部技术、联合疗法和免疫疗法的潜力。最后，该手稿对 HCC 个性化治疗的新目标和策略进行了批判性评估。